HomeAI · summaries
Storia in 2 fonti
MapLight to discuss future of autism drug with FDA despite Phase 2 disappointment
MapLight plans other meet with the FDA after its autism drug ML-004 missed its Phase 2 primary endpoint on social communication but improved irritability in teenagers.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
MapLight to discuss future of autism drug with FDA despite Phase 2 disappointment
MapLight plans other meet with the FDA after its autism drug ML-004 missed its Phase 2 primary endpoint on social communication but improved irritability in teenagers.
- ·
benzinga.com
MapLight Therapeutics Autism Drug Shows Mixed Potential In Adolescents - MapLight Therapeutics (NASDAQ:MP
MapLight's ML-004 misses its main autism study goal but showed notable irritability improvements in adolescents.